---
title: "Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?"
description: "LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atm"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274119354.md"
published_at: "2026-01-30T01:00:00.000Z"
---

# Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

> LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. 

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. 

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. 

For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure.

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, with many uncertainties affecting short-term performance improvement. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas.

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term outflows of funds. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance.

For the subsequent trend, attention needs to be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a short-term technical rebound. Investors should strictly control risks, and when the bottom is unclear, it is advisable to remain on the sidelines. If making tentative layouts, stop-loss levels should be set.

In summary, LUYE PHARMA is currently still in a weak position. During the downward phase, it is essential to closely monitor fund movements and overall market sentiment, as the sector linkage mechanism is unlikely to improve the weakness significantly. Caution is advised for low buying and quick entry and exit operations

### Related Stocks

- [02186.HK - LUYE PHARMA](https://longbridge.com/en/quote/02186.HK.md)
- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274497353.md) |
| 早盘趋势｜三生制药缩量下行，支撑保卫战要开始？ | 1 月 21 日收盘，三生制药（1530.HK）继续震荡下探，盘中成交量持续萎缩，主力资金观望情绪浓厚，抢反弹力量有限。日线级 MACD 死叉形态延续，绿柱扩展，弱势格局短时间内难以逆转。整体来看，市场主导情绪仍为防御，短线资金多数选择快进 | [Link](https://longbridge.com/en/news/273200107.md) |
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| 早盘趋势｜重塑能源缩量盘跌，板块分化中短线机会浮现？ | 2 月 3 日，重塑能源（2570.HK）日 K 线再度下跌，主力拐点尚未明显。新能源赛道整体持续疲弱，内部分化加剧，尤其氢能源本周无落地利好，板块资金流出十分明显。MACD 日线死叉随盘面同步出现，5 日、10 日、20 日均线集体下穿， | [Link](https://longbridge.com/en/news/274626331.md) |
| 早盘趋势｜三生制药缩量下行，支撑保卫战要开始？ | 1 月 21 日收盘，三生制药（1530.HK）继续震荡下探，盘中成交量持续萎缩，主力资金观望情绪浓厚，抢反弹力量有限。日线级 MACD 死叉形态延续，绿柱扩展，弱势格局短时间内难以逆转。整体来看，市场主导情绪仍为防御，短线资金多数选择快进 | [Link](https://longbridge.com/en/news/273209811.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.